Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Albumin
Reexamination Certificate
2011-05-10
2011-05-10
Noakes, Suzanne M (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Albumin
C530S384000, C514S015200, C514S021200
Reexamination Certificate
active
07939632
ABSTRACT:
The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 2005/0266533 (2005-12-01), Ballance et al.
patent: 2009/0298760 (2009-12-01), Weimer et al.
patent: 0 770 625 (1997-05-01), None
patent: 1 444 986 (2004-08-01), None
patent: WO 91/09125 (1991-06-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 01/79271 (2001-10-01), None
patent: WO 02/04598 (2002-01-01), None
patent: WO 02/04598 (2002-01-01), None
patent: WO 03/059935 (2003-07-01), None
patent: WO 03/059935 (2003-07-01), None
patent: WO 03/068934 (2003-08-01), None
patent: WO 03/068934 (2003-08-01), None
patent: WO 2004/021861 (2004-03-01), None
patent: WO 2004/021861 (2004-03-01), None
patent: WO 2004/081053 (2004-09-01), None
patent: WO 2004/101739 (2004-11-01), None
patent: WO 2004/101739 (2004-11-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
patent: WO 2005/001025 (2005-01-01), None
patent: WO 2005/024044 (2005-03-01), None
patent: WO 2005/024044 (2005-03-01), None
patent: WO 2006/018204 (2006-02-01), None
European Search Report; dated Jan. 24, 2007 for App. No. 06012262.9-2403.
Chaudhury, C., et al., The Major Histocompatibility Complex-related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan,J. Exp. Med., 197(3): 315-322 (2003).
Discipio, R.G., et al., A Comparison of Human Prothrombin, Factor IX (Christmas Factor), Factor X (Stuart Factor), and Protein S,Biochemistry, 16(4): 698-706 (1977).
Erhardtsen, E., to General Haemostasis—The Evidence-Based Route,Pathophysiol. Haemost. Thromb., 32(suppl 1): 47-52 (2002).
Ewenstein, B.M., et al., Pharmacokinetic Analysis of Plasma-Derived and Recombinant F IX Concentrates in Previously Treated Patients With Moderate or Severe Hemophilia B,Transfusion, 42: 190-197 (2002).
International Search Report; dated Aug. 22, 2006, for European Patent App. No. 06002359.5, filed Feb. 6, 2006.
Bettini R. et al., Book Review of “Handbook of Pharmaceutical Excipients,” Third Edition, Arthur H. Kibbe (ed.),Journal of Controlled Release, vol. 71, pp. 352-53 (2001).
Colman R.W. et al. (eds.), Excerpts from “Homeostasis and Thrombosis: Basic Principles & Clinical Practice,” 4thed., Philadelphia, Lippincott Williams & Wilkins, 2001, pp. 34-35, 40-41, 103-104, 128-129, 159, 176 and 194.
Kurachi K. et al., “Isolation and Characterization of a cDNA Coding for Human Factor IX,”Proc. Natl. Acad. Sci. U.S.A. Biochemistry, vol. 79, pp. 6461-64 (1982).
Lee G., Book Review of “Pharmaceutical Formulation Development of Peptides and Proteins” by Sven Frokjaer et al.,European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, p. 329 (2000).
Lindley C.M. et al., “Pharmacokinetics and Pharmacodynamics of Recombinant Factor Vila,”Clinical Pharmacology&Therapeutics, vol. 55, No. 6, pp. 638-648 (1994).
Morrissey J.H. et al., “Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation,”The American Society of Hematology, Blood, vol. 81, No. 3, pp. 734-44 (1993).
O'Reilly M.S. et al., “Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin,”Science, vol. 285, pp. 1926-28 (1999).
Prescott M. et al., “The Length of Polypeptide Linker Affects the Stability of Green Fluorescent Protein Fusion Proteins,”Analytical Biochemistry, vol. 273, pp. 305-307 (1999).
Seligsohn U. et al., “Coupled Amidolytic Assay for Factor VII: Its Use with a Clotting Assay to Determine the Activity State of Factor VII,”The American Society of Hematology, Blood,vol. 52, No. 5, pp. 978-988 (1978).
Shah A.M. et al., “Manipulation of the Membrane binding Site of Vitamin K-Dependent Proteins: Enhanced Biological Function of Human Factor VII,”Proc. Natl. Acad. Sci. U.S.A. Biochemistry, vol. 95, pp. 4229-4234 (1998).
Syed S. et al., “Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin,”The American Society of Hematology, Blood, vol. 89, No. 9, pp. 3243-3252 (1997).
Beattie, Wanda G. and Dugaiczyk, Achilles, “Structure and Evolution of Human α-fetoprotein Deduced From Partial Sequence of Cloned cDNA,” Gene, 20: 415-422 (1982).
Cooke, Nancy E. and David, Vivek, E., “Serum Vitamin D-binding Protein is a Third Member of the Albumin and Alpha Fetoprotein Gene Family,” Journal of Clinical Investigation, 76: 2420-2424 (1985).
Wesley, Louise C., et al., “PACE/Furin Can Process the Vitamin K-dependent Pro-factor IX Precursor within the Secretory Pathway,” The Journal of Biological Chemistry, 268: 8458-8465 (1993).
Lichenstein, Henri, et al., “Afamin is a New Member of the Albumin, α-Fetoprotein, and Vitamin D-binding Protein Gene Family,” The Journal of Biological Chemistry, 269: 18149-18154 (1994).
Mollerup, Inger, et al., “The Use of RP-HPLC for Measuring Activation and Cleavage of rFVlla During Purification,” Biotechnology and Bioengineering, 48: 501-505 (1995).
White, Gilbert C., et al., “Recombinant Factor IX,” Thrombosis and Haemostasis, 78: 261-265 (1997).
Aledort, L.M., “Comparative Thrombotic Event Incidence After Infusion of Recombinant Factor Vlla versus Factor VIII Inhibitor Bypass Activity,” Journal of Thrombosis and Haemostasis, 2: 1700-1708 (2004).
Sheffield, William P., et al., “Effects of Genetic Fusion of Factor IX to Albumin on In Vivo Clearance in Mice and Rabbits,” British Journal of Haematology, 126: 565-573 (2004).
International Search Report for application No. PCT/EP2007/005246, Sep. 28, 2007.
Bick R.L. et al., “Physiology of Hemostasis,” Clin. Lab. Med., 14(4):677-707 (1994).
Coleman R.W. et al.,Overview of Hemostasis, inHemostasis and Thrombosis 41hEd., Chapter 1 (Colman et al. eds., Lippincott Williams & Wilkins, 2001).
Greenberg D.L. et al.,Blood Coagulation Factors: Their Complementary DNAs, Genes, and Expression, inHemostasis and Thrombosis 4thEd., Chapter 3, (Colman et al. eds., Lippincott Williams & Wilkins, 2001).
Metzner Hubert
Schulte Stefan
Weimer Thomas
CSL Behring GmbH
Finnegan Henderson Farabow Garrett & Dunner LLP
Noakes Suzanne M
Tsay Marsha M
LandOfFree
Proteolytically cleavable fusion proteins with high molar... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteolytically cleavable fusion proteins with high molar..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteolytically cleavable fusion proteins with high molar... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658677